Antibacterial agent 4, 5-diaryl-thiophen-2-yl hexafluoropropan-2-ol
By developing compounds DNM94A and DNM95A, the inhibitory acyl carrier protein synthase interferes with bacterial lipid metabolism, the problem of resistance of multidrug-resistant bacteria to antibiotics is solved, and effective inhibition of multiple pathogenic bacteria and reducing antibiotic doses is achieved. Effect.
Patent Information
- Application Number
- CN202380032045.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-05
- Filing Date
- 2023-04-05
- Publication Date
- 2024-11-15
AI Technical Summary
The limited effect of existing antibiotics on multidrug-resistant bacteria has led to major challenges in the treatment of infection, and new antibacterial agents are urgently needed to deal with antibacterial resistance.
A compound DNM94A and DNM95A are developed as antibacterial agents or antibacterial adjuvants that interfere with bacterial lipid metabolism by inhibiting acyl carrier protein synthase (AcpS), enhance antibacterial activity, and are used in combination with traditional antibiotics to reduce dose and increase dose Effect.
This compound can effectively fight against Gram-positive, negative bacteria and other pathogenic bacteria, reduce the dosage of antibiotics, and improve the therapeutic effect, especially when fighting multidrug-resistant bacteria, it shows significant antibacterial and bactericidal effects.
Smart Images

Figure CN118974031A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 327,386, filed on April 5, 2022, the contents of which are hereby incorporated in their entirety. Background Art
[0003] Infection is the invasion of a host organism by a foreign organism, generally impairing the host's normal functions. In treating infections and post-infectious inflammatory diseases (e.g., septic shock) in humans and other animals, physicians typically rely on compounds known to have antibiotic effects, whether antiviral, antibacterial, antifungal, etc.
[0004] Unfortunately, many pathogens have become resistant to current antibiotic treatments. Dame Sally Davies, former chief medical officer of the United Kingdom, and Thomas Frieden, director of the Centers for Disease Control and Prevention (CDC) of the United States, have called multidrug resistant (MDR) bacteria "a catastrophic threat to the human population" and "nightmare bacteria", respectively. The World Health Organization (WHO) has identified antibiotic resistance as one of the three greatest threats to human health. A review of antimicrobial resistance shows that there is an urgent need to increase the supply of new antimicrobial agents that are effective against drug-resistant bugs. Currently, 700,000 people die each year worldwide from MDR bacteria, and this number is expected to increase to 10 million if new classes of antibiotics are not introduced into the clinic. Currently, there are less than 40 antibiotics in current clinical trials, none of which are new drug classes that fight new drug targets.
[0005] Therefore, new antimicrobial compounds are needed. Summary of the invention
[0006] The compounds of the present invention can be used to treat infections. In some cases, the compounds themselves are antibacterial agents. In some cases, the compounds ("antibacterial adjuvants") have a beneficial effect in combination with a second antibacterial agent, which, when administered in combination, reduces the dose of antibiotic required for antibacterial activity. In some cases, the compounds are both antibacterial agents and antibacterial adjuvants.
[0007] Generally, in one aspect, a compound of Formula I or a pharmaceutically acceptable salt thereof is provided:
[0008]
[0009] Where R 1 and R 2 are each independently fluorine or chlorine; R 3and R 4 Each is methyl or -CH 2 OH, the premise is that if R 3 is methyl, then R 4 Must be -CH 2 OH, or vice versa; R 5 is hydrogen or alkyl; and R 6 Yes-C(CF 3 ) 2 OH. Embodiments may include one or more of the following. R 1 and R 2 All are chlorine. The compound is 2-(5-(4-chloro-2-(hydroxymethyl)phenyl)-4-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol [hereinafter referred to as "DNM94A"]. The compound is 2-(4-(4-chloro-2-(hydroxymethyl)phenyl)-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol [hereinafter referred to as "DNM95A"].
[0010] In general, in one aspect, a method of treating a bacterial infection is provided, the method comprising administering to a patient in need thereof an effective amount of an antibacterial compound disclosed herein. Embodiments may include one or more of the following. The infection is caused by gram-positive bacteria. The infection is caused by gram-negative bacteria. The infection is caused by acid-fast bacteria. The infection is caused by Bacillus anthracis. The infection is caused by Mycobacterium leprae.
[0011] In general, in one aspect, a method of treating a bacterial infection is provided, the method comprising administering to a patient in need thereof an effective amount of an antibacterial adjuvant compound disclosed herein and an effective amount of an antibacterial compound. Embodiments may include one or more of the following. The infection is caused by gram-positive bacteria. The infection is caused by gram-negative bacteria. The infection is caused by acid-fast bacteria. The infection is caused by Bacillus anthracis. The infection is caused by Mycobacterium leprae. DETAILED DESCRIPTION
[0012] definition
[0013] Unless otherwise defined, the terms used in this specification refer to the following definitions as detailed below.
[0014] The term "administration" or "administering" a compound should be understood to mean providing a compound of the invention to a subject in an amount effective for prophylaxis, treatment or diagnosis, as applicable, in a form that can be introduced into the subject's body. Such forms may include, for example, oral dosage forms, injectable dosage forms, transdermal dosage forms, inhalation dosage forms, and rectal dosage forms.
[0015] As used herein, the term "alkyl" means a straight or branched hydrocarbon containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1, 2, 3, 4, 5 or 6 carbons. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl and n-decyl.
[0016] As used herein, the term "amido" means an amino, alkylamino or dialkylamino group as defined herein, attached to the parent molecular moiety through a carbonyl group. Representative examples of amido include, but are not limited to, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl and ethylmethylaminocarbonyl.
[0017] As used herein, the term "amino" refers to -NH 2 Group.
[0018] As used herein, the term "carbonyl" refers to a -C(=O)- group.
[0019] As used herein, the term "carboxy" refers to a -COOH group, which may be protected as an ester group: -COO-alkyl.
[0020] As used herein, the term "cyano" refers to a -CN group.
[0021] As used herein, the term "dialkylamino" means two independent alkyl groups, as defined herein, attached to the parent molecular moiety through a nitrogen atom. Representative examples of dialkylamino include, but are not limited to, dimethylamino, diethylamino, ethylmethylamino and butylmethylamino.
[0022] As used herein, the term "fluoro" refers to -F.
[0023] As used herein, the term "formyl" refers to a -C(O)H group.
[0024] As used herein, the term "halo" or "halogen" means Cl, Br, I or F.
[0025] As used herein, the term "hydroxy" refers to an -OH group.
[0026] The term "hydroxy-protecting group" means a substituent that protects the hydroxy group from undesired reactions during the synthetic procedure. Examples of hydroxy-protecting groups include, but are not limited to, methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyl, triphenylmethyl, 2,2,2-trichloroethyl, tert-butyl, trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, methylene acetal, acetonide benzylidene acetal, cyclic orthoester, methoxymethylene, cyclic carbonate and cyclic borate. The hydroxyl group-containing compound is prepared by reacting a compound with a base such as triethylamine and a alkyl halide, an alkyl triflate, a trialkylsilyl halide, a trifluoromethanesulfonate trialkylsilyl ester, a trifluoromethanesulfonate aryldialkylsilyl ester or an alkyl chloroformate, CH 2 I 2 The hydroxy protecting group can be attached to the hydroxy group by reacting with a reagent that reacts with a dihaloborate or a dihaloborate, such as methyl iodide, benzyl iodide, triethylsilyl trifluoromethanesulfonate, acetyl chloride, benzyl chloride or dimethyl carbonate. The protecting group can also be attached to the hydroxy group by reacting a compound containing a hydroxy group with an acid and an alkyl acetal.
[0027] As defined herein, the term "imino" means a -C(=NH)- group.
[0028] As used herein, the term "mercapto" refers to a -SH group.
[0029] As used herein, the term "nitro" refers to -NO 2 Group.
[0030] As used herein, the term "nitrogen protecting group" means those groups intended to protect the nitrogen atom from undesired reactions during synthetic procedures. Nitrogen protecting groups include carbamates, amides, N-benzyl derivatives, and imine derivatives. Preferred nitrogen protecting groups are acetyl, benzoyl, benzyl, benzyloxycarbonyl (Cbz), formyl, benzylsulfonyl, pivaloyl, tert-butyloxycarbonyl (Boc), tert-butylacetyl, trifluoroacetyl, and triphenylmethyl (trityl). The nitrogen protecting group is attached to the primary or secondary amino group by reacting the compound containing the amine group with a base such as triethylamine and a reagent selected from alkyl halides, alkyl trifluoromethanesulfonates, dialkyl anhydrides (e.g. represented by (alkyl-O)2C=O), diaryl anhydrides (e.g. represented by (aryl-O)2C=O), acyl halides, alkyl chloroformates or alkylsulfonyl halides, arylsulfonyl halides or halo-CON(alkyl)2, such as acetyl chloride, benzoyl chloride, benzyl bromide, benzyloxycarbonyl chloride, formyl fluoride, benzenesulfonyl chloride, pivaloyl chloride, (tert-butyl-OC=O)2O, trifluoroacetic anhydride and triphenylmethane.
[0031] As used herein, the term "oxo" means (=0).
[0032] Unless otherwise indicated, the term "prodrug" encompasses pharmaceutically acceptable esters, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphates, metal salts, and sulfonates of the compounds disclosed herein. Examples of prodrugs include compounds comprising a biohydrolyzable moiety (e.g., a biohydrolyzable amide, a biohydrolyzable carbamate, a biohydrolyzable carbonate, a biohydrolyzable ester, a biohydrolyzable phosphate, or a biohydrolyzable ureide analog). Prodrugs of the compounds disclosed herein are readily conceived and prepared by one of ordinary skill in the art. See, e.g., Design of Prodrugs, Bundgaard, A. Ed., Elseview, 1985; Bundgaard, hours., “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Krosgaard-Larsen and hours. Bundgaard, Ed., 1991, Chapter 5, p. 113-191; and Bundgaard, hours., Advanced Drug Delivery Review, 1992, 8, 1-38.
[0033] Unless otherwise indicated, the term "protecting group (protecting group / protective group)" when used to refer to a portion of a molecule subjected to a chemical reaction means a chemical portion that is not reactive under the conditions of the chemical reaction and can be removed to provide a portion that is reactive under those conditions. Protecting groups are well known in the art. See, for example, Greene, TW and Wuts, PGM, Protective Groups in Organic Synthesis (3rd ed., John Wiley & Sons: 1999) (Greene TW and Wuts, PGM, Protective Groups in Organic Synthesis (3rd ed., John Wiley & Sons: 1999); Larock, RC, Comprehensive Organic Transformations (2nd ed., John Wiley & Sons: 1999) (Larock RC Comprehensive Organic Transformations, 2nd ed., John Wiley & Sons: 1999). Some examples include benzyl, diphenylmethyl, triphenylmethyl, Cbz, Boc, Fmoc, methoxycarbonyl, ethoxycarbonyl, and pthalimido. Protecting groups include, for example, nitrogen protecting groups and hydroxy protecting groups.
[0034] As used herein, the term "sulfonyl" refers to -S(O) 2 -group.
[0035] Some compounds of the present invention can exist as stereoisomers in which asymmetric or chiral centers are present. These stereoisomers are "R" or "S", depending on the configuration of the substituents around the chiral carbon atom. As used herein, the terms "R" and "S" are configurations defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, in Pure Appl. Chem., 1976, 45: 13-30 (IUPAC 1974 "Pure and Applied Chemistry" in the basic stereochemistry section E, 1976, 45: 13-30). The present invention contemplates various stereoisomers and mixtures thereof, and these substances are specifically included within the scope of the present invention. Stereoisomers include enantiomers and diastereomers and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds may be prepared synthetically from commercially available starting materials that contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well known to those of ordinary skill in the art. These resolution methods are exemplified by: (1) attaching a mixture of enantiomers to a chiral auxiliary, separating the resulting mixture of diastereomers by recrystallization or chromatography and optionally liberating the optically pure product from the auxiliary, as described in Furniss, Hannaford, Smith and Tatchell, "Vogel's Textbook of Practical Organic Chemistry" 5th edition (1989), Longman Scientific & Technical, Essex CM202JE, England, which is incorporated herein by reference for its disclosure of methods for separation and purification of diastereomers; or (2) direct separation of a mixture of optical enantiomers on a chiral chromatographic column; or (3) fractional recrystallization methods.
[0036] Certain compounds of the invention may exist as cis or trans isomers, where the substituents on the ring may be attached in such a way that they are on the same side of the ring relative to each other (cis) or on opposite sides of the ring relative to each other (trans). Such methods are well known to those of ordinary skill in the art and may include separation of isomers by recrystallization or chromatography. It should be understood that the compounds may have tautomeric forms as well as geometric isomers, and these compounds also constitute an aspect.
[0037] It should be noted that a chemical moiety that forms part of a larger compound may be described herein using the name commonly given to it when it exists as a single molecule or the name commonly given to its free radical. For example, the terms "pyridine" and "pyridyl" are given the same meaning when used to describe moieties attached to other chemical moieties. Thus, for example, the two phrases "XOH, where X is pyridyl" and "XOH, where X is pyridine" are given the same meaning and cover the compounds pyridine-2-ol, pyridine-3-ol, and pyridine-4-ol.
[0038] It should also be noted that names of compounds having one or more chiral centers without specifying the stereochemistry of those centers encompass both pure stereoisomers and mixtures thereof. Furthermore, any atom shown in the drawings with unsatisfied valences is assumed to be attached to sufficient hydrogen atoms to satisfy the valences. Additionally, chemical bonds depicted with a solid line parallel to a dashed line encompass both single and double bonds (e.g., aromatic) if valences permit.
[0039] As used herein, the term "pharmaceutically acceptable excipient" means a non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials that can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol and phosphate buffered solutions, and other nontoxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as colorants, release agents, coating agents, sweeteners, flavoring and fragrance agents, preservatives and antioxidants may also be present in the composition according to the judgment of those skilled in the art of formulation.
[0040] Unless otherwise indicated, a "therapeutically effective amount" of a compound is an amount sufficient to treat a disease or condition, or one or more symptoms associated with the disease or condition. In some embodiments, "treatment" can be determined by comparison to an untreated control.
[0041] The term "subject" is intended to include living organisms in which a disease may occur. Examples of subjects include humans, monkeys, cows, sheep, goats, dogs, cats, mice, rats, and transgenic species thereof.
[0042] The present invention is based at least in part on the design of compounds that inhibit acyl carrier protein (ACP) synthase (AcpS), which is responsible for converting apo-ACP into holo-ACP. AcpS is not only present in gram-positive and gram-negative bacteria, but also in acid-fast bacteria such as mycobacterium tuberculosis, and even in protozoa such as Plasmodium falciparum. Therefore, it is expected that AcpS inhibitors will have an adverse effect on the vitality of many microorganisms. It is expected that AcpS inhibitors will have an adverse effect on the maintenance of bacterial cell function, including, for example, increased porosity of the cell membrane and dysfunction of efflux pumps in such membranes. In some embodiments, the compound is an AcpS inhibitor.
[0043] In some embodiments, the compound has an antibacterial effect when not administered with other antibiotics. In some embodiments, the compound may have an antibacterial adjuvant effect ("adjuvant" or "pro-antibiotic") or other synergistic effect when administered with antibiotics such as colistin, azithromycin, erythromycin, ampicillin, rifampicin, clofazimine or other antibiotic compounds described herein. In some embodiments, the compound is an antibacterial or antibacterial adjuvant for Gram-positive bacteria.
[0044] Although the utility of the compounds disclosed herein does not essentially depend on whether they are AcpS inhibitors, the design effect towards this goal at least partially caused the discovery of the compounds disclosed herein. Although it is not desired to be bound by a particular theory or hypothesis, the inventors believe that by inhibiting AcpS in bacteria, the compounds of the present invention interfere with the basic cellular function of lipid metabolism in bacteria. This interference with bacterial lipid metabolism may greatly affect the maintenance of bacterial cell membranes, which is expected to produce porous membranes that allow antibacterial compounds to enter, and the antibacterial compounds would otherwise be unable to pass through intact bacterial cell membranes. In addition, it is expected that the efflux pumps generally present in bacterial cell membranes are insufficient to remove the antibacterial compounds that are in possible concentrations in bacteria with porous membranes. These and other factors may be related to the mechanism of the antibacterial adjuvants described herein.
[0045] According to one embodiment, there is provided a compound according to one of Formula I, or a prodrug or a pharmaceutically acceptable salt thereof:
[0046]
[0047] Where R 1 and R 2 are each independently fluorine or chlorine; R 3 and R 4 Each is methyl or -CH 2 OH, the premise is that if R 3 is methyl, then R 4 Must be -CH 2 OH, or vice versa; R 5 is hydrogen or alkyl; and R 6 Yes-C(CF 3 ) 2 OH. In some embodiments, R 1 and R 2 All are chlorine. In some embodiments, the compound is 2-(5-(4-chloro-2-(hydroxymethyl)phenyl)-4-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol. In some embodiments, the compound is 2-(4-(4-chloro-2-(hydroxymethyl)phenyl)-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol.
[0048] According to one embodiment, a method of treating bacterial infection is provided, the method comprising administering an effective amount of an antibacterial compound as described herein to a patient in need thereof. In some embodiments, the gram-positive bacteria is Bacillus anthracis. In some embodiments, the gram-positive bacteria is Staphylococcus aureus. In some embodiments, the compound is an antibacterial or an antibacterial adjuvant for gram-negative bacteria. In some embodiments, the gram-negative bacteria is Pseudomonas, such as Pseudomonas aeruginosa. In some embodiments, the gram-negative bacteria is Klebsiella, such as Klebsiella pneumoniae. In some embodiments, the gram-negative bacteria is Acinetobacter, for example Acinetobacter baumannii. In some embodiments, the compound is an antibacterial or an antibacterial adjuvant for acid-fast bacteria. In some embodiments, the acid-fast bacteria is Mycobacterium, such as Mycobacterium leprae.
[0049] In some embodiments, the bacterial infection is caused substantially by gram-positive bacteria. In some embodiments, the bacterial infection is caused substantially by enterococci. In some embodiments, the bacterial infection is caused substantially by staphylococci. In some embodiments, the bacterial infection is caused substantially by bacillus. In some embodiments, the bacterial infection is caused substantially by staphylococcus epidermidis, staphylococcus aureus (including methicillin-resistant staphylococcus aureus [MRSA]), enterococcus (including vancomycin-resistant enterococci [VRE]), streptococcus, bacillus or mycobacterium. In some embodiments, the infection is polymicrobial. The statement that bacterial infection is "substantially caused by specific bacteria or its species" indicates that a given bacterial genus or species is considered to be the main cause of the pathology, epidemiology or symptom profile of bacterial infection, and does not exclude the presence of other bacterial species (e.g., benign colonization bacteria). In some embodiments, the bacterial infection is a skin and skin structure ulcer infection, a wound infection, a diabetic foot infection, osteomyelitis, pneumonia, leprosy, anthrax infection, impetigo or secondary acquired traumatic lesions, gastroenteritis, meningitis, pneumonia, gonorrhea, peptic ulcer, nosocomial infection or bloodstream infection, etc. In some embodiments, the antibacterial agents described are used as pharmaceutical compounds, such as for treating humans, or as veterinary compounds, such as for treating animals, poultry, livestock, etc., and in aquaculture and agricultural applications.
[0050] According to one embodiment, a method of treating bacterial infection is provided, the method comprising applying an effective amount of an antibacterial adjuvant compound as described herein and an effective amount of an antibacterial compound to a patient in need. In some embodiments, the antibacterial adjuvant compound itself is an antibacterial agent to some extent. Therefore, not only the combination of the compounds of the present invention with each other is possible, but also the combination between the compounds of the present invention and known antibacterial compounds is possible. In some embodiments, the bacterial infection is skin and skin structure ulcer infection, wound infection, leprosy, anthrax, diabetic foot infection, osteomyelitis, pneumonia, impetigo or secondary acquired traumatic lesions, gastroenteritis, meningitis, pneumonia, sepsis, urinary tract infection, gonorrhea, peptic ulcer, hospital infection, bloodstream infection, brucellosis, campylobacteriosis, cat scratch fever, cholera, legionellosis, leptospirosis, Lyme disease, melioidosis, meningitis, whooping cough, plague, salmonellosis, shigellosis, syphilis, tularemia, typhoid fever or urinary tract infection. An effective amount of one or more of the antibacterial agents described above can be used to prepare a medicament as described above for treating a disease, disorder or condition caused by a pathogen selected from the group including, but in no way limited to, Escherichia, Klebsiella, Salmonella, Pseudomonas, Neisseria, Legionella, Haemophilus, Campylobacter, Helicobacter and Shigella.
[0051] In another embodiment, a method of making a medicament for treating a bacterial infection is provided, the method comprising mixing an antibacterial compound as described herein with a suitable excipient.
[0052] In other embodiments, there is provided use of an antibacterial compound as described herein for treating a bacterial infection.
[0053] In another embodiment, a method of making a medicament for treating a bacterial infection is provided, the method comprising admixing an antibacterial adjuvant as described herein with a suitable antibacterial compound.
[0054] In other embodiments, there is provided use of an antibacterial adjuvant as described herein for treating a bacterial infection. In some embodiments, an antibacterial adjuvant is used or co-administered with an antibacterial compound.
[0055] According to one embodiment, a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable excipient is provided.
[0056] Notably, the antibacterial agent or antibacterial adjuvant can be prepared or formulated for administration in a variety of ways, such as topically, orally, intravenously, intramuscularly, subcutaneously, intraperitoneally, intranasally, or by local or systemic intravascular infusion using means known in the art and as discussed below.
[0057] Antibacterial or antibacterial adjuvant compounds can be arranged to be delivered at a concentration of about 1nM to about 50mM, or 10nM to about 50mM, or 100nM to about 50mM, or 1μM to about 50mM, or 10μM to 50mM or 100μM to 50mM. As will be appreciated by those skilled in the art, this can be an "effective amount", i.e., administering sufficient dosages so that a concentration within one of the envisioned ranges is obtained at the desired site. In some antibacterial embodiments, the effective amount will be at least partially affected by the minimum inhibitory concentration of the compound required for the antibacterial or bactericidal effect on the pathogen of interest. In some antibacterial adjuvant embodiments, the effective amount will be at least partially affected by the approximate minimum concentration required for the desired adjuvant effect of the pathogen of interest produced by a predetermined known antibiotic. In some embodiments, the effective amount will be calibrated so as to produce a serum content of more than ten times the MIC, or more than five times the MIC, or more than three times the MIC, or at the MIC in the subject suffering from infection. In some embodiments, the effective amount will be calibrated to produce an in situ concentration that is ten times greater than the MIC, or five times greater than the MIC, or three times greater than the MIC, or at the MIC.
[0058] One of the compounds of the effective amount may be used in pure form, or in the case of such forms, in the form of a pharmaceutically acceptable salt. Alternatively, the compound may be administered in the form of a pharmaceutical composition containing a combination of the compound of interest and one or more pharmaceutically acceptable carriers. However, it should be understood that the total daily dosage of the compound and composition will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dosage level for any particular patient will depend on a variety of factors, including the severity of the condition being treated and the condition; the activity of the specific compound being used; the specific composition being used; the patient's age, weight, general health, sex and diet; the time of administration, route of administration and excretion rate of the specific compound being used; the duration of treatment; the risk / benefit ratio; drugs used in combination or concurrently with the specific compound being used; and similar factors well known in the medical field. For example, it is well known to those skilled in the art to start the compound dosage at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.
[0059] The total daily dose of the compound of the present invention administered to humans or lower animals can be in the range of about 0.0003 mg / kg body weight to about 30 mg / kg body weight. For the purpose of oral administration, a more preferred dosage can be in the range of about 0.0003 mg / kg body weight to about 1 mg / kg body weight. If desired, the effective daily dose can be divided into multiple doses for administration purposes; therefore, a single-dose composition can contain such an amount or its fraction to constitute a daily dose. For oral administration, the composition is preferably provided in the form of a tablet containing about 1.0 mg, about 5.0 mg, about 10.0 mg, about 15.0 mg, about 25.0 mg, about 50.0 mg, about 100 mg, about 250 mg or about 500 mg of active ingredient.
[0060] In order to obtain the best results, whether a particular compound is an antibacterial agent or an antibacterial adjuvant with respect to the pathogen of interest (and in the case of an adjuvant, with respect to the second antibacterial compound used) will generally be determined by a number of microbiological methods known in the art, including, for example, the methods disclosed in the Examples. It is well understood in the art that while each "antibacterial" compound has an antibacterial effect on at least one pathogen in one or more effective amounts, the antibacterial compounds differ in their spectrum and / or potency of activity. In addition, while each "antibacterial adjuvant" compound has an adjuvant effect on at least one pathogen in combination with at least one antibacterial compound in one or more effective amounts of both the antibacterial compound and the adjuvant, the antibacterial adjuvant compounds differ in their spectrum, potency of activity, and / or compatibility with the particular antibacterial compound. As will be apparent to those skilled in the art, the total dosage will vary according to many factors, including, but by no means limited to, the weight, age, and condition of the individual or patient.
[0061] In some embodiments, one or more antibacterial compounds can be co-administered with one or more known antibiotics. In some embodiments, one or more antibacterial adjuvant compounds can be co-administered with one or more antibacterial compounds; in this case, the total effective amount of the antibacterial compound can be lower than the total effective amount required in the absence of the antibacterial adjuvant in other aspects, for example, 8 times lower, or 16 times lower, or 32 times lower, or 64 times lower, or 125 times lower, or 250 times lower. In some embodiments, the antibacterial adjuvant compound itself is not an antibacterial. In some embodiments, the antibacterial adjuvant compound itself is an antibacterial. In some embodiments, one or more antibacterial adjuvant compounds can be combined with one or more antibacterial compounds in a single dosage form. In some embodiments, the antibacterial compound is an antibacterial compound of the present invention. In some embodiments, the antibacterial compound is a known antibacterial compound such as amethicillin, amdenocillin, amikacin, amoxicillin, amphotripsy, amphotericin B, ampicillin, azacitidine, azaserine, azithromycin, azlocillin, aztreonam, artemisinin, allopurinol, amicacin, aminoglycoside, amphotericin B, ampicillin, ansamycin, anthracycline, antimycotic, azithromycin, bacillin, bacitracin, benzyl penicillin, bacitracin, ... penicilloyl-polylysine), bleomycin, brefeldin A, butoconazole, candidicide, capreomycin, carbenicillin, cefaclor, cefadroxil, cefamandole, cefazolin, cefdinir, cefepime, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone, cefoperazone, cefotetan, cefotetan, cefotiam, cefoxitin, cefpiramide, cefpodoxime, cefprozil, cefsulodin, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefuroxime, cefacenitrile, cephalexin, cefuroxime, cephalothin, cefpirin, cephradine, chloramphenicol, cilastatin, Cinnamycin, ciprofloxacin, clarithromycin, clavulanic acid, clindamycin, clioquinol, clofazimine, cloxacillin, polymyxin E mesylate, colistin, cyclopentyl penicillin, cycloserine, cyclosporine, cyclo(leucine-proline), camptothecin, cefotaxime, cephalexin, cephalosporin, chalcomycin, chlortetracycline, chlortetracycline, chlortetracycline, chlortetracycline, chlortetracycline, chlortetracycline, chlortetracycline M, chlortetracycline V, clomocycline, actinomycin D, dalbavancin, dalfopristin, daptomycin, daunorubicin, demeclocycline, detopicin, dicloxacillin, dihydrostreptomycin, dirithromycin, doxorubicin, doxycycline, ellipticine, elsamicin, epirubicin, erythromycin,eveminomycin, filipin, fluconazole, nystatin, fusidic acid, flucloxacillin, fosfomycin, gentamicin, fusin, griseofulvin, griseofulvin, guanomecycline, gemifloxacin, gramicidin, hetacillin, idarubicin, imipenem, iseganan, ivermectin, ilosamide, itraconazole, kanamycin, aspartame, linezolid, loracarb spore, lancomycin, lincomycin, magainin, meclocycline, meropenem, methacycline, mezlocillin, minocycline, mitomycin, moenomycin, latamoxef, moxifloxacin, mycophenolic acid, macrolide, methicillin, mitoxantrone, nafcillin, natamycin, neomycin, netilmicin, nifilmycin, nitrofurantoin, novobiocin, nalidixic acid, norfloxacin, nystatin, nystatin, ofloxacin, oleandomycin, oxytetracyline, paromomycin, penicillamine, phenoxyethyl penicillin, Piperacillin, plicamycin, pristinamycin, pecillocin, penicillin, pesticides, phosphomycin, pimarcin, plate mycin, polyene, polymyxin B, polymyxin E, quinupristin, quinolone, lavamycin, reserpine, rifamycin, ristocetin A and ristocetin B, rifabutin, rifampicin (rifampicin / rifampin), rifamycin, hydropyricycline, sisomicin, spiramycin, spironolactone, sulfamethoxazole sodium, sulfa, Spectinomycin, streptomycin, streptozotocin, sulbactam, sultamicin, tacrolimus, tazobactam, teicoplanin, telithromycin, terramycin, tetracycline, thiamphenicol, thiocandin, tobramycin, gramicidin, ticarcillin, tigecycline, tobramycin, troleandomycin, tunicamycin, gramicidin, vancomycin, vidarabine, puromycin, virginiamycin and wortmannin; the presence of multiple items in the foregoing list means one or more members of the antibiotic family known in the art with the foregoing name. Which one or more compounds should be co-administered or combined with the compounds of the present invention depends on many factors, including but not necessarily limited to the efficacy of the one or more agents in the absence of an antibacterial adjuvant compound in a subject, the mechanism of action of the compound, the identity of the pathogen causing or exacerbating the condition, and / or the severity of the condition. ,
[0062] The pharmaceutical composition can be formulated for oral administration in solid or liquid form, parenteral intravenous, subcutaneous, intramuscular, intraperitoneal, intraarterial or intradermal injection, or vaginal, nasal, external or rectal administration. The pharmaceutical composition of the present invention suitable for oral administration can be present in discrete dosage forms such as tablets, chewable tablets, caplets, capsules, liquids and flavored syrups. Such dosage forms contain a predetermined amount of active ingredient and can be prepared by pharmaceutical methods known to those skilled in the art. Generally refer to Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990) ("Remington's Pharmacy", 18th edition, Mack Publishing Company, Easton Township, Pennsylvania (1990)).
[0063] Parenteral dosage forms can be administered to patients by various routes, including subcutaneous, intravenous (including bolus injection), intramuscular and intra-arterial. Because their administration usually bypasses the patient's natural defense against contaminants, parenteral dosage forms are particularly sterilized or can be sterilized before being administered to the patient. Examples of parenteral dosage forms include ready-to-inject solutions, ready-to-dissolve or suspended in pharmaceutically acceptable injection vehicles, ready-to-inject suspensions and emulsions. Pharmaceutical compositions for parenteral injections include pharmaceutically acceptable sterilized aqueous or non-aqueous solutions, dispersions, suspensions or emulsions and sterilized powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc. and suitable mixtures thereof), vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate) or suitable mixtures thereof. The suitable fluidity of the composition can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of a dispersion and by using a surfactant. These compositions can also contain adjuvants, such as preservatives, wetting agents, emulsifiers and dispersants. The defense against microbial action can be ensured by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents, such as sugar, sodium chloride, etc. The extended absorption of injectable drug forms can be achieved by using agents that delay absorption such as aluminum monostearate and gelatin.
[0064] In some cases, in order to prolong the action of a drug, it is often desirable to slow down the absorption of the drug from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline or amorphous material with poor water solubility. The absorption rate of the drug then depends on its dissolution rate, which in turn may depend on the crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is achieved by dissolving or suspending the drug in an oil vehicle.
[0065] In addition to the active compound, the suspension may also contain suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tragacanth and mixtures thereof. If desired, and in order to be more effectively distributed, the compound may be incorporated into a system such as a polymer matrix, liposome and microsphere for sustained release or targeted delivery. They may be sterilized, for example, by filtering through a bacteria-retaining filter or by incorporating a sterilizing agent in the form of a sterilized solid composition, which may be dissolved in sterile water or some other sterilized injectable medium immediately before use.
[0066] The injectable depot form is manufactured by forming a microencapsulation matrix of the drug in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of the drug to the polymer and the properties of the specific polymer used, the drug release rate can be controlled. The examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable preparations are also prepared by embedding the drug in a liposome or microemulsion compatible with body tissues. The injectable preparation can be sterilized, for example, by filtering through a bacteria-blocking filter or by incorporating a sterilizing agent in the form of a sterilized solid composition, which can be dissolved or dispersed in sterile water or other sterilized injectable media just before use.
[0067] Injectable preparations, such as sterile injectable aqueous or oily suspensions, can be prepared according to known techniques using suitable dispersants or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions in nontoxic, parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, USP and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspension media. For this purpose, any mild fixed oil can be used, and the fixed oil includes synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectables.
[0068] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, one or more compounds are mixed with at least one inert pharmaceutically acceptable carrier such as sodium citrate or dicalcium phosphate and / or the following: a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and salicylic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarder such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glyceryl monostearate; h) absorbents such as kaolin and bentonite; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0069] Solid compositions of similar types may also be used as fillers in soft and hard-filled gelatin capsules using lactose (lactose / milk sugar) and high molecular weight polyethylene glycol. Solid dosage forms of tablets, dragees, capsules, pills and granules may be prepared with coatings and shells such as enteric coatings and other coatings known in the field of pharmaceutical formulation. They may optionally contain opacifiers and may also be compositions that release active ingredients only or preferentially in a delayed manner in a specific portion of the intestinal tract. Examples of materials that can be used to delay the release of active agents may include polymeric substances and waxes.
[0070] Dosage forms for topical administration may include powders, sprays, ointments and inhalants. The compounds of the invention may be mixed with a pharmaceutically acceptable carrier and any desired preservatives, buffers or propellants that may be required under sterile conditions. Ophthalmic preparations, ophthalmic ointments, powders and solutions within the scope of the invention are contemplated. Aqueous liquid compositions comprising the compounds are also contemplated.
[0071] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form may also contain an inert diluent commonly used in the art, such as water or other solvents, solubilizers and emulsifiers such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (specifically, cottonseed oil, wild bean oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan and mixtures thereof.
[0072] In addition to inert diluents, oral compositions may also include adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and aromatics. The dosage form for external or transdermal administration of the compound of the present invention includes ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The desired compound is mixed with a pharmaceutically acceptable carrier and any required preservatives or buffers that may be needed under sterile conditions. Ophthalmic preparations, eye drops, ophthalmic ointments, powders and solutions within the scope of the present invention are also contemplated. In addition to the active compound of the present invention, ointments, pastes, creams and gels may also contain animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicones, bentonite, silicic acid, talcum and zinc oxide or mixtures thereof.
[0073] Powders and sprays can contain, in addition to the compounds of this invention, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain conventional propellants such as chlorofluorohydrocarbons.
[0074] The compound can also be administered in the form of liposomes. As known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by monolayer or multilayer hydrated liquid crystals dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipids capable of forming liposomes can be used. In addition to the compound, the composition of the present invention in the form of liposomes may also contain stabilizers, preservatives, etc. Preferred lipids are natural and synthetic phospholipids and phosphatidylcholine (lecithin) used independently or together. The method for forming liposomes is known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, NY, (1976), p 33 et seq (Prescott, "Cell Biology Methods", Volume XIV, Academic Press, New York, (1976), page 33 and the following, etc.).
[0075] In some embodiments, one or more antimicrobial agents or antimicrobial adjuvants in the concentrations or dosages discussed above may be combined with a biodegradable or non-biodegradable pharmaceutically or pharmacologically acceptable carrier, excipient, or diluent. Illustrative examples of carriers include, but are by no means limited to, for example, poly(ethylene-vinyl acetate), copolymers of lactic acid and glycolic acid, poly(lactic acid), gelatin, collagen matrix, polysaccharides, poly(D,L-lactide), poly(malic acid), poly(caprolactone), cellulose, albumin, starch, casein, dextran, polyester, ethanol, methacrylate, polyurethane, polyethylene, vinyl polymers, glycols, mixtures thereof, and the like. Standard excipients include gelatin, casein, lecithin, acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycol, polyoxyethylene stearate, colloidal silicon dioxide, phosphate esters, sodium lauryl sulfate, calcium carboxymethylcellulose, sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, amorphous cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinyl pyrrolidone, sugars and starches.
[0076] As will be apparent to one skilled in the art, specific carriers and carrier combinations known in the art may be selected based on their properties and release characteristics in view of the intended use. Specifically, the carrier may be pH sensitive, thermosensitive, thermogelling, arranged for sustained release or fast burst. In some embodiments, different classes of carriers may be used in combination to obtain multiple effects, such as a fast burst followed by sustained release.
[0077] In other embodiments, one or more antimicrobial agents or antimicrobial adjuvants in the concentration or dosage described above can be encapsulated for delivery. Specifically, the compound can be encapsulated in a biodegradable microsphere, microcapsule, microparticle or nanosphere. The delivery vehicle can be composed of, for example, hyaluronic acid, polyethylene glycol, poly (lactic acid), gelatin, poly (E-caprolactone) or poly (lactic acid-glycolic acid) polymer. Combinations can also be used, because, for example, gelatin nanospheres can be coated with poly (lactic acid-glycolic acid) polymers. As is apparent to those skilled in the art, these and other suitable delivery vehicles can be prepared and used to deliver the compound according to protocols known in the art.
[0078] It is noteworthy that the antibacterial agents described above can be combined with penetration enhancers known in the art to improve delivery. Examples of penetration enhancers include, but are by no means limited to, those compounds described in: U.S. Pat. Nos. 3,472,931; 3,527,864; 3,896,238; 3,903,256; 3,952,099; 4,046,886; 4,130,643; 4,130,667; 4,299,826; 4,335,115; 4,343,798; 4,379, No. 454; No. 4,405,616; No. 4,746,515; No. 4,788,062; No. 4,820,720; No. 4,863,738; No. 4,863,970; and No. 5,378,730; British Patent No. 1,011,949; and Idson, 1975, J. Pharm. Sci. 64:901-924.
[0079] "Pharmaceutically acceptable salts" include salts that retain the desired biological activity of the parent antibacterial or antibacterial adjuvant compound and do not impart any undesired toxicological effects. Examples of such salts are salts of acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc., acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, benzoic acid, pamoic acid, alginic acid, methanesulfonic acid, naphthalenesulfonic acid, etc. Also included are salts of cations such as sodium, potassium, lithium, zinc, copper, barium, bismuth, calcium, etc., or organic cations such as trialkylammonium. Combinations of the above salts are also useful. It should be understood that the compounds disclosed herein in salt-free form and similar compounds in the form of pharmaceutically acceptable salts are compounds of the present invention. In addition, prodrugs, such as esters of compounds disclosed herein, are compounds of the present invention. If the acid addition salts, carboxylates, amino acid addition salts and zwitterionic salts of the compounds of the present invention are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction, etc., within the scope of reasonable medical judgment, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, their preparation and use may also be considered pharmaceutically acceptable. Such salts may also include various solvates and hydrates of the compounds of the present invention.
[0080] In some embodiments, the antimicrobial compounds described are used as pharmaceutical compounds, such as for treating humans, or as veterinary compounds, such as for treating animals, poultry, livestock, etc., and in aquaculture and agricultural applications.
[0081] While various embodiments have been described above, it will be recognized and understood that modifications may be made therein and that the appended claims are intended to cover all such modifications that may fall within the spirit and scope.
[0082] Certain embodiments will now be described using examples.
[0083] Example 1
[0084] Synthesis of 2-(4-(4-chloro-2-(hydroxymethyl)phenyl)-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol
[0085]
[0086] Synthesis of 4-bromo-5-(4-chloro-2-methylphenyl)thiophene-2-carbaldehyde (2)
[0087] 4,5-Dibromothiophene-2-carboxaldehyde 1 (2.0 g, 7.41 mmol, 1.0 equivalent), 4-chloro-2-methylphenylboronic acid (1.2 g, 7.04 mmol, 0.95 equivalent), Pd(PPh 3 ) 4 (0.428 g, 0.37 mmol, 0.05 eq), Na 2 CO 3 (1.57 g, 14.8 mmol, 2.0 equiv)) was added to a flame-dried round-bottom flask. Dioxane:H 2 O mixture (20mL: 6mL), and the resulting reaction mixture was purged with argon for 15 minutes. The reactants were heated at a temperature of about 95°C for 12 hours, during which time the starting material was observed to be completely consumed in TLC. The reactants were cooled to room temperature, diluted with water, and extracted with EtOAc. The combined organic layers were washed with water and washed with Na 2 SO 4 Dry, filter, and remove the solvent under reduced pressure. The resulting residue was purified by flash column chromatography (5% EtOAc in hexanes) to give the title compound 4-bromo-5-(4-chloro-2-methylphenyl)thiophene-2-carbaldehyde 2 (1.9 g, 82%) as a yellow-green liquid.
[0088] Synthesis of 1-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-2,2,2-trifluoroethan-1-ol (3)
[0089] 4-Bromo-5-(4-chloro-2-methylphenyl)thiophene-2-carboxaldehyde 2 (1.90 g, 6.03 mmol, 1.0 equiv) in anhydrous THF (20 mL) was treated with trimethyl(trifluoromethyl)silane (1.20 mL, 7.84 mmol, 1.3 equiv) at 0 °C, followed by tetrabutylammonium fluoride solution (1 M in THF, 0.2 mL, 0.1 equiv). The reactants were stirred at room temperature for 30 minutes. OTMS intermediate formation was observed. A stoichiometric amount of tetrabutylammonium fluoride solution (1 M in THF, 2.0 mL, 1.0 equiv) was added to the reaction mixture to cleave the OTMS intermediate. The reactants were stirred at room temperature for another 3 hours. After the reaction was complete, it was diluted with EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with water and washed with Na 2 SO 4 Dry and remove the solvent under reduced pressure. The resulting residue was purified by flash column chromatography (10% EtOAc in hexanes) to give the title compound 1-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-2,2,2-trifluoroethan-1-ol 3 (1.62 g, 70.1%) as a yellow liquid.
[0090] Synthesis of 1-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-2,2,2-trifluoroethan-1-one (4)
[0091] 1-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-2,2,2-trifluoroethan-1-ol 3 (1.62 g, 4.22 mmol, 1.0 eq) was dissolved in DCM (16 mL) and Dess-Martin periodinane (3.6 g, 8.43 mmol, 2 eq) was added portionwise at 0 °C over a period of 30 min. The reaction was stirred for an additional 3 h at room temperature. After the reaction was complete, it was diluted with DCM and water. The aqueous layer was extracted with DCM and the combined organic layers were washed with water and washed with Na 2 SO 4 Dry and remove the solvent under reduced pressure. The resulting residue was purified by flash column chromatography (3% EtOAc in hexanes) to give the title compound 1-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-2,2,2-trifluoroethan-1-one 4 (1.40 g, 70.1%) as a white liquid.
[0092] Synthesis of 2-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol (5)
[0093] 1-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-2,2,2-trifluoroethan-1-one 4 (1.40 g, 3.65 mmol, 1.0 equiv) in anhydrous THF (14 mL) was treated with trimethyl(trifluoromethyl)silane (1.0 mL, 7.28 mmol, 2.0 equiv) at 0 °C and then with tetrabutylammonium fluoride solution (1 M in THF, 0.1 mL, 0.1 equiv). The reactants were stirred at room temperature for 30 minutes. The formation of the OTMS product as an intermediate was observed. A stoichiometric amount of tetrabutylammonium fluoride solution (1 M in THF, 1.0 mL, 1.0 equiv) was added to the reaction mixture to cleave the OTMS intermediate. The reactants were stirred at room temperature for 7 hours. After the reaction was complete, it was diluted with EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with water and washed with Na 2 SO 4 The resulting residue was purified by flash column chromatography (10% EtOAc in hexanes) to give the title compound 2-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol 5 (0.86 g, 52.12%) as a viscous liquid.
[0094] Synthesis of 2-(4-(4-chloro-2-(hydroxymethyl)phenyl)-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol (6)
[0095] 2-(4-bromo-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol 5 (0.86 g, 1.89 mmol, 1.0 equiv), (4-chloro-2-(hydroxymethyl)phenyl)boronic acid (0.42 g, 2.27 mmol, 1.2 equiv), Pd(PPh 3 ) 4 (0.11 g, 0.094 mmol, 0.05 eq), Na 2 CO 3 (0.6 g, 5.68 mmol, 3.0 equiv) was added to a flame-dried round-bottom flask. Dioxane:H 2 O mixture (10mL: 5mL), and the resulting reaction mixture was purged with argon for 15 minutes. Thereafter, the reaction mixture was heated at a temperature of about 100°C for 12 hours, during which time complete consumption of the starting material was observed in TLC. The reactants were cooled to room temperature, diluted with water, and extracted with EtOAc (3×30mL). The combined organic layers were washed with water and washed with Na 2 SO 4The resulting residue was purified by flash column chromatography (20% EtOAc in hexanes) and then lyophilized to give the title compound 2-(4-(4-chloro-2-(hydroxymethyl)phenyl)-5-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol 6 (0.62 g, 64%) as a colorless solid. 1 H NMR (300 MHz, CDCl 3 )δ(ppm)7.47(d,J=2.1Hz,1H),7.35(s,1H),7.19–7.07(m,4H),6.94(d,J=8.2Hz,1H),4.41(s,2H),2.00(s,3H); 13 C NMR (75MHz, CDCl 3 )δ(ppm)140.94,140.05,139.10,137.44,134.86,134.30,132.80,132.66,131.98,131.25,13 0.68,130.60,130.32,128.58,127.95,126.23,124.10,120.29,77.36,76.42,62.50,20.36; C 21 H 14 Cl 2 F 6 O 2 ESI-HRMS calculated value of S: 513.9996 Actual value m / z: 512.9940 [MH] - ; Purity according to HPLC: 98.85% (t R =9.89 minutes).
[0096] Example 2
[0097] Synthesis of 2-(5-(4-chloro-2-(hydroxymethyl)phenyl)-4-(4-chloro-2-methylphenyl)thiophen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol
[0098] This compound was synthesized generally following the procedure of Example 1, except that the order of addition of the boronic acid was reversed, using (4-chloro-2-(hydroxymethyl)phenyl)boronic acid in the first step and 4-chloro-2-methylphenylboronic acid in the last step.
[0099] Example 3
[0100] Measuring Minimum Inhibitory Concentration (MIC)
[0101] Bacillus anthracis bacterial inoculum was prepared by suspending the colonies in sheep blood agar plates (BAP) for 18-24 hours (h). The Bacillus anthracis plates were incubated at 35°C for 36-48 hours. The MIC was determined in 96-well microplates by microdilution method according to CLSI guidelines (Clinical and Laboratory Standards Institute, 2015).
[0102] The following table indicates the results of compound experiments showing antibacterial effects of compounds DNM94A, DNM95A, ciprofloxacin and colistin against a number of strains of Bacillus anthracis (GT64 = greater than 64 μg / ml):
[0103]
[0104] All values listed are in μg / ml.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt thereof: wherein R1 and R2 are each independently fluorine or chlorine; R3 and R4 are each methyl or -CH2OH, provided that if R3 is methyl, then R4 must be -CH2OH, or vice versa; R5 is hydrogen or alkyl; and R6 is -C(CF3)2OH.
2. The compound according to claim 1, wherein R1 and R2 are each chlorine.
3. The compound of claim 2, wherein R3 is methyl, R4 is -CH2OH, and R5 is H.
4. The compound of claim 2, wherein R3 is -CH2OH, R4 is methyl, and R5 is H.
5. A method of treating a bacterial infection, the method comprising administering to a patient in need thereof an effective amount of an antibacterial compound according to any one of the preceding claims.
6. The method of treatment according to claim 5, wherein the bacterial infection is essentially caused by Gram-positive bacteria.
7. The method of treatment according to claim 6, wherein the bacterial infection is substantially caused by Bacillus anthracis.
8. The method of treatment according to claim 5, wherein the bacterial infection is substantially caused by acid-fast bacteria.
9. A method of treatment according to claim 8, wherein the bacterial infection is substantially caused by Mycobacterium leprae.
10. The method of treatment according to claim 5, wherein the bacterial infection comprises an enterococcal infection.
11. The method of treatment according to claim 5, wherein the bacterial infection is substantially caused by a species selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Enterococcus faecium, Bacillus cereus and Streptococcus.
12. A method of treating bacterial infection, comprising administering to a patient in need thereof an effective amount of an antibacterial adjuvant compound according to any one of claims 1 to 4 and an effective amount of an antibacterial compound.
13. The method of treatment according to claim 12, wherein the bacterial infection is essentially caused by Gram-negative bacteria.
14. The method of treatment according to claim 12, wherein the bacterial infection is caused essentially by Gram-positive bacteria.
15. The method of treatment of claim 12, wherein the bacterial infection is polybacterial.
16. The method of treatment according to claim 12, wherein the bacterial infection is substantially caused by a species selected from the group consisting of Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii and Escherichia coli.
17. The method of treatment according to claim 12, wherein the antibacterial compound is selected from the group consisting of colistin, ampicillin, erythromycin and azithromycin.
18. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 and a pharmaceutically acceptable excipient.
19. Use of a compound according to any one of claims 1 to 4 for treating a bacterial infection.
20. Use of a compound according to any one of claims 1 to 4 as an antibacterial adjuvant for the treatment of bacterial infections.
Citation Information
Patent Citations
Centrifugal wheel blasting machine
GB1011949A
Percutaneous absorption with lower alkyl amides
US3472931A
